HomeOwner SearchCategory Search
Visit USCOAnti-Cancer Drugs [Published: 2017-08-23 to 2017-09-20. Issues: vol. 28, no. 8, September 2017 to vol. 28, no. 9, October 2017]
Serial Registration
Copyright Title
Anti-Cancer Drugs [Published: 2017-08-23 to 2017-09-20. Issues: vol. 28, no. 8, September 2017 to vol. 28, no. 9, October 2017]
Status
Published
on 9 Oct 2018
Year of Creation
2017
Copyright Claimant
Wolters Kluwer
Registration Number
TX0008657133
on 9 Oct 2018Copyright Summary
The U.S. Copyright record (Registration Number: TX0008657133) dated 9 Oct 2018, pertains to an electronic file (eService) titled "Anti-Cancer Drugs [Published: 2017-08-23 to 2017-09-20. Issues: vol. 28, no. 8, September 2017 to vol. 28, no. 9, October 2017]" created in 2017. The copyright holder is Wolters Kluwer, known for their creative contributions in serial registration. For any inquiries concerning this copyrighted material, kindly reach out to Wolters Kluwer.
Application Details
Registration Number
TX0008657133
Registration Date
10/9/2018
Year of Creation
2017
Agency Marc Code
DLC-CO
Record Status
New
Corporate Author
Wolters Kluwer
First Publication Nation
United States
Notes
Rights Note: LWW Permissions, Wolters Kluwer, 351 W. Camden St., Baltimore, MD, 21201, United States, permissions@lww.com
Copyright Local Holdings: vol. 28, no. 8, September 2017 Pub. 2017-08-23 Reg. 2018-10-11 TX0008657133 PSTANvol. 28, no. 9, October 2017 Pub. 2017-09-20 Reg. 2018-10-11 TX0008657133 PSTAN
Statements
Application Title Statement: Anti-Cancer Drugs
Author Statement: Wolters Kluwer employer for hire Authorship: collective work
© 2024 reserved by Trademarkia
Show terms & conditions
Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.